Personalized treatment for lung cancer is evolving faster than professional organizations can issue treatment guidelines.
In October, the American Society of Clinical Oncology (ASCO) endorsed the 2013 molecular testing guidelines issued jointly by the International Association for the Study of Lung Cancer and two pathology organizations. These guidelines set standards to test for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene translocations. Randomized clinical trials underlying these guidelines showed that, in patients with these tumor mutations, targeted drugs yield better response rates and progressionfree survival than chemotherapy. These drugs include the EGFR tyrosine kinase inhibitors gefitinib and erlotinib and ALK inhibitors crizotinib and ceritinib.
But practices had already widely adopted such testing. Lung cancer specialist Paul Bunn, M.D., of the University of Colorado, estimated that only 20% of U.S. oncology practices don't test advanced lung tumors for EGFR and ALK mutations. "It's not totally clear how to get to that 20%," he said. "ASCO can help with adoption by making [the guidelines] well known."
As those remaining practices gradually adopt tumor genetic testing, academic medical centers and many community oncology practices have already moved on, greatly expanding its scope. Besides EGFR and ALK, research has found more than a dozen other genetic alterations in driver oncogenes in non-small-cell lung cancer. Doctors are already testing for these and prescribing drugs according to the results. 
Varied Reactions to Benzene
Developed over years of successive crossbreeding, the DO model addresses a substantial limitation in toxicology: Cohorts of traditional inbred mice-which show little genetic diversity-respond similarly to drug or chemical exposures in a study. By contrast, human populations are genetically diverse, and individual responses vary depending on susceptibility to a particular outcome. This disparity is problematic; assuming that inbred strains misrepresent the typical human response can lead to a standard that over-or underprotects human health.
During the new study, slated for February publication in Environmental Health Perspectives, investigators exposed Mass., is marketing its Foundation One test, which sequences 236 cancer genes and identifies gene fusions for 19 others. Company spokesman Dan Budwick said that Foundation Medicine reported 9,000 test results to oncologists in 2013 and was on pace for 23,500-25,000 test reports in 2014, with half of orders coming from community-based oncologists.
"That's phenomenally rapid growth in just a year, and we're going to see that continue," Stella said.
How should oncologists advise patients who test positive? In lung cancer, "there's no guidelines to say that you should look for BRAF mutations or look for RET fusions or look for uncommon EGFR mutations, because there's no established approved treatment for those," Bunn said. In theory, patients can enroll in investigational drug clinical trials. Such trials are under way individually for most, but not all, identified genetic alterations in non-small-cell lung cancer.
Several large trials designed to steer more lung cancer patients to panels of experimental targeted therapies are also in progress:
• The Southwest Oncology Group launched the Lung Cancer Master Protocol (Lung-MAP) trial in June 2014 for advanced squamous-cell lung cancer.
• Foundation Medicine will test up to 1,000 patients per year for mutations in 200 genes and match them with one of four targeted agents or anti-PD-L1 immunotherapy.
• The Lung Cancer Mutation Consortium 2 trial has already tested more than 800 lung adenocarcinoma patients for 14 oncogenic drivers and matched them with targeted therapies in an ongoing trial.
• The Eastern Cooperative Oncology
Group sponsors the Molecular Analysis for Therapy Choice (NCI-MATCH) trial, which will enroll patients with solid tumors and lymphomas that have progressed on standard therapy. Testing for alterations in 200-300 genes will result, for an estimated one-third to one-half of patients, in treatment with one of 40 investigational targeted agents, matched to tumor genetic profile.
But these trials will capture only a few patients, and other important trials will remain undone. Although many genes that FDA-approved drugs target are mutated in multiple tumor types, "there just aren't enough patients in these rare subsets, there's not enough money to do all these trials, there's not enough time to do them all," Schilsky said. So doctors simply offer patients the drugs. "There's nothing right now, of course, to stop a doctor from prescribing one of these drugs off-label, except for the fact that these drugs tend to be very expensive and oftentimes the payer won't cover them," Schilsky said.
With a monthly drug cost of at least $8,000, many patients cannot afford to pay out-of-pocket. Yet doctors increasingly prescribe such drugs after tumor genomic testing, and some insurance companies are paying "under the radar," Stella said. Unfortunately, the clinical data are lost to the field.
"We have no idea what's happening out there in the country where all these oneoffs are being done," Stella said. "You have no idea if the patient responded or not." ASCO has a plan to help patients get off-label treatment with FDA-approved drugs and to capture outcome data from such use. The Target Agent Profiling and Utilization Registry (TAPUR) calls for doctors who order tumor genomic profiling to check results against a molecular treatment protocol and treat patients accordingly, or otherwise to submit a treatment plan to a molecular tumor board. Drug companies will supply the drugs at no cost and insurance companies will cover routine clinical care. In return, the patient and doctor agree to submit the clinical data to a registry that all parties can access. These data could help drug companies decide whether an approved drug is worth formally testing in a different indication. Companies have been receptive to the TAPUR concept, Schilsky said, and ASCO will launch a pilot project in a limited number of sites.
So even without formal guidelines, a system for off-label use of targeted cancer drugs (and data collection) should soon be available to community oncologists. Stella embraces the concept, in part because broad genomic testing, beyond EGFR and ALK, is so available. "It's becoming the standard of care," he said.
